[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
IJRR Information::
For Authors::
For Reviewers::
News & Events::
Web Mail::
Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
Hard Copy 2322-3243
Online 2345-4229
Online Submission
Now you can send your articles to IJRR office using the article submission system.



:: Volume 19, Issue 1 (1-2021) ::
Int J Radiat Res 2021, 19(1): 213-221 Back to browse issues page
Radioiodine (131-I) treatment for Graves’ disease: Geant4 Monte Carlo simulation for patient personalized dose estimation
S. Meftah , T. Kraïem , S. Elj , A. Ben-Ismail
Laboratory of Biophysics and Medical Technologies of Tunis, Tunis, Tunisia , sabrine.meftah1@gmail.com
Abstract:   (2576 Views)
Background: Reliable estimation of radiation-absorbed dose is necessary to evaluate the benefits and the risks of radiopharmaceuticals used for diagnostic or therapeutic purposes in nuclear medicine. Materiel and Methods: This study included 47 patients treated with iodine-131 for Graves’ disease. A comparative study between Geant4 Monte Carlo simulation and MIRD formalism was carried out to evaluate the dose received by each patient. Patients’ thyroids and internal radiation were modeled using Geant4. Geant4 simulations were compared to experimental measurements performed with TLDs placed inside an ellipsoidal Thyroid phantom. MIRD was used to determine the beta doses received by the different patients. Results: The average difference between MIRD and Geant4 considering only beta emitted radiation was approximately 5.6%; this difference is justified by the fact that, Geant4, contrary to MIRD, considers all particle energies of the 131I spectrum, the shape of the thyroid and the heterogeneity of the dose deposited in the modeled volume. A good agreement was found between experiment and Geant4 simulations. The total dose received by patients varies between 176Gy and 359Gy. After 9 month, 74% of treated patients were rendered hypothyroid. Conclusion: This study showed the necessity of determining the specific activity of each patient considering the thyroid volume and the iodine fixation. It also revealed that the Geant4 toolis appropriate for accurate internal dosimetry calculations, particularly for the case of Graves’ disease treatment. GEANT4 can be used as a standard for the comparison of experimental measurements.
Keywords: 131-I, MIRD, Geant4 simulations, TLD.
Full-Text [PDF 1909 kb]   (1040 Downloads)    
Type of Study: Original Research | Subject: Medical Physics
Send email to the article author

Add your comments about this article
Your username or Email:


XML     Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Meftah S, Kraïem T, Elj S, Ben-Ismail A. Radioiodine (131-I) treatment for Graves’ disease: Geant4 Monte Carlo simulation for patient personalized dose estimation. Int J Radiat Res 2021; 19 (1) :213-221
URL: http://ijrr.com/article-1-3479-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 19, Issue 1 (1-2021) Back to browse issues page
International Journal of Radiation Research
Persian site map - English site map - Created in 0.05 seconds with 50 queries by YEKTAWEB 4652